Results 201 to 210 of about 131,822 (267)
Some of the next articles are maybe not open access.
Medical Clinics of North America, 2014
Primary care providers (PCPs) are frequently responsible for the pharmacologic management of mood disorders, and the PCP is often an important member of the clinical team in the management of bipolar disorder and schizophrenia. Not only is a good understanding of psychopharmacology important for the effective treatment of psychiatric disease, it is ...
L Renata, Thronson +1 more
openaire +2 more sources
Primary care providers (PCPs) are frequently responsible for the pharmacologic management of mood disorders, and the PCP is often an important member of the clinical team in the management of bipolar disorder and schizophrenia. Not only is a good understanding of psychopharmacology important for the effective treatment of psychiatric disease, it is ...
L Renata, Thronson +1 more
openaire +2 more sources
Italian Journal of Dermatology and Venereology, 2018
Most dermatologists evaluate and treat patients with psychological or psychiatric issues related to their skin disease. These patients often require psychopharmacologic therapies. Therefore, it is important for dermatologists to be familiar with psychopharmacologic treatments for diseases that fit into the overlap between psychiatry and dermatology ...
Sahil, Sekhon +2 more
openaire +2 more sources
Most dermatologists evaluate and treat patients with psychological or psychiatric issues related to their skin disease. These patients often require psychopharmacologic therapies. Therefore, it is important for dermatologists to be familiar with psychopharmacologic treatments for diseases that fit into the overlap between psychiatry and dermatology ...
Sahil, Sekhon +2 more
openaire +2 more sources
Psychopharmacological Interventions
Child and Adolescent Psychiatric Clinics of North America, 2008Currently stimulants and atomoxetine are the most established treatments for attention deficit hyperactivity disorder (ADHD); more than 170 controlled studies with more than 9000 subjects have documented their efficacy in 50% to 70% of subjects. Although the stimulant medications tend to show a dose-related improvement in ADHD symptoms, atomoxetine is ...
Joseph, Biederman, Thomas J, Spencer
openaire +2 more sources
NeuroRehabilitation, 1993
This article examines the use of compounds classified as “cognitive activators” to treat cognitive deficits from neurologic disorders, particularly brain injury. The compounds reviewed include catecholamine agonists, cholinergic agonists, nootropics, gangliosides, and thyrotropin releasing hormone (TRH).
A, McLean +3 more
openaire +2 more sources
This article examines the use of compounds classified as “cognitive activators” to treat cognitive deficits from neurologic disorders, particularly brain injury. The compounds reviewed include catecholamine agonists, cholinergic agonists, nootropics, gangliosides, and thyrotropin releasing hormone (TRH).
A, McLean +3 more
openaire +2 more sources